The induction of antigen-specific adaptive immunity exclusively occurs in lymphoid organs.A saconsequence,t he efficacy by which vaccines reach these tissues strongly affects the efficacy of the vaccine.H ere,w er eport the design of polymer hydrogel nanoparticles that efficiently target multiple immune cell subsets in the draining lymph nodes.N anoparticles are fabricated by infiltrating mesoporous silica particles (ca. 200 nm) with poly(methacrylic acid) followed by disulfide-based crosslinking and template removal. PEGylation of these nanoparticles does not affect their cellular association in vitro,but dramatically improves their lymphatic drainage in vivo.T he functional relevance of these observations is further illustrated by the increased priming of antigenspecific Tcells.O ur findings highlight the potential of engineered hydrogel nanoparticles for the lymphatic delivery of antigens and immune-modulating compounds.
Modulating Tand Bcell immunity not only is key to the development of improved and new vaccines against pathogens,but also holds great promise to treat malignancies,autoimmune diseases,and allergies. [1, 2] Priming of Tcell responses requires the presentation of antigens,i nt he format of processed peptide fragments loaded onto major histocompatibility complexes,bydendritic cells (DCs). Priming of Bcells and their differentiation into antibody secreting plasma cells relies on surface triggering of the Bcell receptor (BCR) by antigens.P revious studies have shown that the priming of naïve Tand Bcells can be dramatically enhanced by delivering antigens formulated as nano-or microparticles. [1] [2] [3] [4] [5] [6] Compared to soluble antigens,p articulate vaccines enhance the quality and the magnitude of the adaptive immune response by acting on different levels.A tt he level of the DC,t hey increase antigen uptake and improve antigen presentation to Tcells qualitatively and quantitatively.P eptide fragments of particulate antigens are loaded onto MHCII and MHCI molecules and thus can evoke both CD4 and CD8 Tcell responses.Bycontrast, soluble antigens are almost exclusively presented via MHCII molecules,r esulting in an immune response restricted to CD4 Tcells.Att he level of the Bcell, the display of multiple antigen copies at the particle surface dramatically increases activation of Bcells by simultaneous triggering of multiple BCRs on the Bcell surface. [7] Tcell and Bcell priming exclusively occur in secondary lymphoid organs.A sac onsequence,t he efficacyw ith which vaccine carriers reach these sites constitutes ac ritical determinant of their efficacytoinduce adaptive immunity and thus ultimately affects the protective efficacyo ft he vaccine. [8] [9] [10] [11] As vaccines are commonly delivered by intramuscular or subcutaneous injection, lymph nodes are the lymphoid organs vaccines need to target. To move from the site of injection to lymph nodes,v accines must be either transported actively to the lymph nodes by tissue DCs or they need to move along the interstitial flow,a cross the extracellular matrix, into the lymphatics. [12] As the latter process does not involve cellular uptake for transport, it is called passive drainage.T he way particles drain to lymph nodes,a nd the efficacy with which they reach antigen-presenting cells,m ainly depends on their in situ mobility after injection. Particles that show limited mobility in the extracellular matrix rely on local DCs recruited to the injection site for uptake and transport. Such particles become surrounded by fibrous tissue and become engulfed predominantly by tissue macrophages.A sac onsequence,o nly am inor fraction of particle-delivered antigens will reach the lymph nodes and contribute to the induction of the antigen-specific immune response.M oreover,t he longterm presence of particles at the injection site creates an antigen depot that could cause exhausted Tc ell responses, and could hamper vaccine elicited protection. [13, 14] In contrast, particles with high mobility in the extracellular matrix can move along the interstitial flow and thus have better potential to reach the lymph nodes,either after uptake by tissue DCs or after passive entry into the lymphatics.S imilar requirements are needed for nanomaterial-based sentimental lymph node mapping. [15] [*] Dr.S .DeKoker, [ 
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However,t here is much debate on the size and physicochemical properties of particles required to ensure optimal lymph node targeting and often particle uptake in vitro is ap oor predictor of in vivo particle mobility.I nt his context, PEGylation [i.e., surface modification with poly(ethylene glycol)] might improve the mobility of nanocarriers in the extracellular matrix following subcutaneous injection. PEGylation has shown to be as uccessful strategy to increase the half-life of proteins and nanoparticles in systemic circulation after intravenous injection by reducing the interaction with macrophages and serum proteins. [16] Here,w ea ddress the impact of PEGylation on the lymphatic drainage properties of reduction-sensitive hydrogel nanoparticles and its influence on the subsequent priming of Tcells.
Mesoporous silica (MS) nanoparticles with an average size of 200 nm were synthesized according to ap reviously reported method. [17, 18] Hydrogel nanoparticles are fabricated by infiltrating amine-modified MS nanoparticles with pyridine dithioethylamine (PDA-) modified poly(methacrylic acid) (PMA PDA ). Subsequently,c ysteamine (SH-) modified poly(methacrylic acid) (PMA SH )i si nfiltrated, leading to crosslinking by disulfide exchange (Figure 1) . [19] To track particle uptake,f luorescent labeling was performed with Alexa Fluor 488-cadaverine (AF488) prior to dissolution of the silica template particles in buffered HF solution. Since there are both residual thiols and pyridyldisulfides remaining in the PMA nanoparticles,P EGylation was performed by grafting maleimide-functionalized poly(ethylene glcyol) (PEG MAL )a nd thiol-functionalized PEG (PEG SH )o nto the PMA nanoparticles.F igure 1B shows transmission electron microscopy (TEM) images of the MS template nanoparticles and the resulting PMA nanoparticles,a nd af luorescence microscopy image of the nanoparticles.T he TEM images demonstrate the porous nature of the silica templates and as imilar diameter compared to the original MS templates. Dynamic light scattering (DLS) confirms the TEM data, showing an average particle size of 200 nm (polydispersity index, PDI:0.07) for the MS templates and 185 nm (PDI:0.1) for the PMA nanoparticles in ahydrated state (see Figure S1 in the Supporting Information). Also note that PEGylation does not significantly alter the size and morphology of the nanoparticles.T he fluorescence microscopy image in Figure 1C shows that the PMA nanoparticles are well-dispersed in aqueous solution. By counting the nanoparticles by flow cytometry and measuring the fluorescence of an anoparticle suspension by fluorimetry ( Figure S2 ) we verified that both PMA and PEG-PMA nanoparticles bear similar fluorescence.
To investigate the interaction between the hydrogel nanoparticles and DCs in vitro,w ei ncubated DCs with PMA and PEG-PMA nanoparticles followed by confocal microscopy and quantitative analysis using flow cytometry (FACS). Confocal microscopy of (Figure 2A )t he cell membrane stained by AlexaFluor647-conjugated cholera toxin subunit B( AF647-CTB) demonstrated massive internalization of the nanoparticles by DCs.N oo bvious differences in cell interaction between both types of nanoparticles were observed from these images. Figure 2B shows flow cytometry data in terms of the percentage of nanoparticle-associated cells and their mean fluorescence.N anoparticle uptake appears to proceed in an energy-dependent fashion, since minimal cellular association occurred at 4 8 8Cb ut it significantly increased at 37 8 8Ce ven without any difference in nanoparticle-cell association between PMA and PEG-PMA nanoparticles.T og ain more insight into the intracellular localization of the nanoparticles by DCs,w eu sed stochastic optical reconstruction microscopy (STORM), as uper-resolution microscopy technique that allows sub-diffractionlimited features to be resolved. [21] Figure 2C and Ds how awhole DC and part of aDC, respectively,whereas Figure 2E depicts as eries of relevant events during the internalization process of the nanoparticles.T hese pictures show at high resolution the engulfment of the nanoparticles by the plasma membrane ( Figure 2E1 ), lipid raft-mediated routing (Figure 2E2 ) and finally storage of the nanoparticles in endo/ lysosomal vesicles ( Figure 2E3 ). Themost striking feature of these images is that they enable imaging at single-particle and single-endo/phago/lysosomer esolution. CTB specifically binds to the ganglioside G M1 that is present on the plasma membrane of DCs,i np articular at sites that are involved in lipid raft-mediated endocytosis. [20] In this case,italso provides an avenue for labeling lipid rafts and becomes incorporated in endo/lysosomal membranes,a ss hown in Figure 2E .T his set of data is,t ot he best of our knowledge,a mongst the first showing the potential of super-resolution microscopy for assessing the intracellular fate of nanoparticles.N ote that trafficking of antigen in intracellular vesicles does not hamper efficient antigen presentation. [22] Although PEGylation does not affect the uptake of 200 nm sized PMA and PEG-PMA nanoparticles by DCs in vitro,i tm ight significantly enhance their mobility and lymph node drainage behavior in vivo.T oa ddress this, 
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Communications AF488-labeled nanoparticles were injected subcutaneously into the footpad of mice followed by flow cytometry (FACS) analysis (gating strategy is depicted in Figure S3 ) of the draining lymph nodes at 12 and 48 h, post injection. Importantly,w en oticed that neither PMA nor PEG-PMA nanoparticles induced significant swelling of the lymph nodes, which gives proof of their non-inflammatory nature.Bcells were identified as CD3À and CD19+ + cells.L ymph node macrophages were determined as CD3À,C D19À,C D64+ +, and CD11b+ + cells.D Cs were defined as CD3À,C D19À, CD11c+ +,a nd MHCII+ + cells.B ased on their relative expression of MHCII and CD11c, lymph node DCs were subdivided into migratory DCs (CD11c int MHCII hi )a nd lymph noderesident DCs (CD11c hi MHCII int ). [12, 23] Migratory DCs in lymph nodes represent tissue DCs that have migrated from peripheral tissue to the lymph nodes,w hile lymph noderesident DCs have spent their life cycle in the lymph nodes without prior presence in peripheral sites.
Within these respective populations,w ed etermined the percentage of nanoparticle-associated cells and the intensity of the AF488 fluorescence signal within the particle positive population. Flow cytometry graphs of particle uptake are shown in Figure S4 . Thec orresponding quantitative analysis ( Figure 3A )p roves that significantly higher percentages of Bcells,m acrophages,m igratory DCs and lymph node-resident DCs were associated with PEG-PMA nanoparticles compared to PMA nanoparticles at 12 and 48 hpost injection
On ac ell-per-cell basis,t he number of particles strongly increased in the case of PEG-PMA nanoparticles.Atthe DC level, migratory DCs associated more nanoparticles on acellper-cell basis when compared to resident DCs.T his indicates that active transport of nanoparticles by DCs from the skin is an important mediator of both PEG-PMA and PMA nanoparticle drainage.N evertheless,n anoparticles were also strongly present in non-migratory lymph node cells including macrophages,Bcells,a nd lymph node-resident DCs,w hich suggests passive drainage of the nanoparticles also occurs.T o further characterize the lymph node drainage properties of the nanoparticles,w ea nalyzed their intranodal distribution. As can be seen from Figure 3B ,h igher numbers of PEG-PMA nanoparticles were present in the lymph nodes compared to PMA nanoparticles,confirming the FACS data. The majority of the nanoparticles were seen in the subcapsular sinus that lines the lymph nodes and in the Bcell zone lying immediately beneath. Thes ubcapsular sinus is the port of entry for all particles draining from the tissue,being either as free flowing particles or particles actively transported inside migratory DCs.T he subcapsular sinus contains vast amounts of macrophages that capture free particles that arrive through the afferent lymph and transport the particles to Bcells in the follicles beneath the capsular floor. Indeed, as shown in Figure 3C ,many PEG-PMA nanoparticles are located at the border region between the subcapsular sinus and the Bcell follicles,w hich also explains their high association with macrophages and Bcells in FACS analysis.I mportantly, nanoparticles were also visible in the deeper paracortex areas of the lymph node,where they are in the close presence of Tcells (dashed rectangles in Figure 3C ). Confocal microscopy images of sorted DCs and Bcells ( Figure 3D )a lso confirm internalization of the nanoparticles by these immune cell subsets.
Particles transported by migratory DCs have been reported to mostly end up in DCs in the Tcell areas of the draining lymph nodes.P articles transported through active and passive transport show aw ider cellular and subanatomical distribution pattern in the lymph node,r eaching Bcell follicles in addition to Tcell areas.A saconsequence,t he intranodal distribution of the PEG-PMA nanoparticles,their presence in Bcells,resident DCs and macrophages alongside with their high numbers in the migratory DC population strongly suggest that PEG-PMA nanoparticles drain to the lymph nodes through both active transport and passive lymphatic flow.P EGylation enforces both routes of transportation and our data demonstrate that PEGylation dramatically improves the lymph node targeting properties of PMA nanoparticles.Most likely,this can be attributed to the decreased fouling behavior of PEG-PMA versus non-PEGylated PMA nanoparticles.P MA SH -based capsules have been reported to strongly interact with cysteine residues of proteins present on the cell surface. [24] In the present work, blocking the residual-free thiol and pyridyldisulfide groups of the nanoparticles by PEGylation reduces the interaction of PMA nanoparticles with the extracellular matrix and thereby dramatically improves their lymphatic transportation.
Finally,w ei nvestigated whether the increased lymph trafficking behavior of PEG-PMA nanoparticles translates into superior antigen presentation to Tcells in the lymph nodes.T herefore,w ec onjugated the MHCI epitope (SIIN-FEKL) of the model antigen ovalbumin (OVA )toboth PMA and PEG-PMA nanoparticles.T his was performed by conjugating the cysteine-terminated peptide (i.e., CSIINFEKL) to PMA PDA by thiol-disulfide exchange,f ollowed by nanoparticle fabrication. Mice were immunized with the peptideloaded nanoparticles and antigen presentation was assessed by measuring the proliferation of adoptively transferred, CFSE-labeled transgenic OVA-specific OT-I Tc ells in the draining lymph nodes.OT-ITcells are transgenic CD8 Tcells with aTcell receptor that specifically recognizes the SIIN-FEKL epitope of OVA. FACS (gating strategy is given in Figure S5 ) can easily trace the number of OT-I divisions as the CFSE fluorescence signal halves each time the Tcell divides. As shown in Figure 4 , PEG-PMA nanoparticles evoked significantly more OT-I proliferation when compared to their non-PEGylated peptide bearing counterparts.T his clearly demonstrates that delivery of the peptide by the PEGylated particles results in increased antigen presentation and augmented Tcell priming.
In summary,w eh ave demonstrated that PEGylation strongly improved lymph node targeting of hydrogel nanoparticles.More lymph node DCs and Bcells became particle positive and the number of particles on ac ell per cell basis increased dramatically,e specially within the migratory DCs that originate from the injection site.This increased presence of particles in the lymph nodes resulted in increased priming of antigen-specific Tcells.A lthough we did not analyze the humoral immune response-peptides are known to be poor inducers of antibody responses-this feature is likely to improve Bcell activation by increased triggering of the cell surface Bcell receptor and thus to lead to improved antibody responses to vaccination. Finally,inaddition to the delivery of antigens,P EGylation of PMA nanoparticles also holds potential to improve the delivery of molecular adjuvants and drugs to the lymph nodes. Figure 4 . In vivo CD8 Tcell response measured by quantifying the extent of proliferationo fantigen-specific CD8 Tcells in the spleen of mice that were immunized with either PEG-PMA or PMA nanoparticles. A) FACS histogramsa nd B) corresponding percentage of antigenspecific CD8 Tcells that underwentm ore than eight divisions. (n = 3; ***: p < 0.001).
